Cost-effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States

OBJECTIVES: The phase 3 trial, RESPOND-2, demonstrated that the addition of boceprevir (BOC) to peginterferon-ribavirin (PR) resulted in significantly higher rates of sustained virologic response (SVR) in previously treated patients with chronic hepatitis C virus (HCV) genotype-1 infection as compar...

Full description

Saved in:
Bibliographic Details
Main Authors: Chhatwal, Jagpreet, Ferrante, Shannon A., Brass, Cliff, El Khoury, Antoine C., Burroughs, Margaret, Bacon, Bruce, Esteban-Mur, Rafael, Elbasha, Elamin H.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3820000/
https://ncbi.nlm.nih.gov/pubmed/24041347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jval.2013.07.006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items